Risk of Clinically Significant Prostate Cancer after a Nonsuspicious Prostate MRI—A Comparison with the General Population
Open Access
- 25 January 2024
- journal article
- research article
- Published by American Association for Cancer Research (AACR) in Cancer Epidemiology, Biomarkers & Prevention
- Vol. 33 (5) , 749-756
Abstract
Background: We compare the risk of clinically significant (csPCa; ISUP Grade Group ≥ 2) and insignificant prostate cancer (isPCa; ISUP Grade Group 1) in men with a nonsuspicious prostate MRI (nMRI; PI-RADS ≤ 2) with the general population, and assess the value of PSA density (PSAD) in stratification. Methods: In this retrospective population-based cohort study we identified 1,682 50–79-year-old men, who underwent nMRI at HUS (2016–2019). We compared their age-standardized incidence rates (IR) of csPCa and the odds of isPCa to a local age- and sex-matched general population (n = 230,458) during a six-year follow-up. Comparisons were performed by calculating incidence rate ratios (IRR) and ORs with 95% confidence intervals (CI). We repeated the comparison for the 920 men with nMRI and PSAD < 0.15 ng/mL/cm3. Results: Compared with the general population, the IR of csPCa was significantly higher after nMRI [1,852 vs. 552 per 100,000 person-years; IRR 3.4 (95% CI, 2.8–4.1)]. However, the IR was substantially lower if PSAD was low [778 per 100,000 person-years; IRR 1.4 (95% CI, 0.9–2.0)]. ORs for isPCa were 2.4 (95% CI, 1.7–3.5) for all men with nMRI and 5.0 (95% CI, 2.8–9.1) if PSAD was low. Conclusions: Compared with the general population, the risk of csPCa is not negligible after nMRI. However, men with nMRI and PSAD <0.15 ng/mL/cm3 have worse harm-benefit balance than men in the general population. Impact: Prostate biopsies for men with nMRI should be reserved for cases indicated by additional risk stratification. See related In the Spotlight, p. 641Keywords
All Related Versions
Funding Information
- Cancer Foundation of Foundation (180141)
- Competitive State Research Funding (TYH2021332)
- Jane ja Aatos Erkon Säätiö (29.5.202)
This publication has 27 references indexed in Scilit:
- Negative Multiparametric Magnetic Resonance Imaging for Prostate Cancer: What's Next?European Urology, 2018
- The diagnostic accuracy of multiparametric magnetic resonance imaging before biopsy in the detection of prostate cancerBJU International, 2018
- MRI-Targeted or Standard Biopsy for Prostate-Cancer DiagnosisNew England Journal of Medicine, 2018
- Quality measures of the population-based Finnish Cancer Registry indicate sound data quality for solid malignant tumoursEuropean Journal of Cancer, 2017
- Diagnostic accuracy of multi-parametric MRI and TRUS biopsy in prostate cancer (PROMIS): a paired validating confirmatory studyThe Lancet, 2017
- The influence of prostate‐specific antigen density on positive and negative predictive values of multiparametric magnetic resonance imaging to detect Gleason score 7–10 prostate cancer in a repeat biopsy settingBJU International, 2016
- Combination of prostate imaging reporting and data system ( PI ‐ RADS ) score and prostate‐specific antigen ( PSA ) density predicts biopsy outcome in prostate biopsy naïve patientsBJU International, 2016
- The 2014 International Society of Urological Pathology (ISUP) Consensus Conference on Gleason Grading of Prostatic CarcinomaAmerican Journal of Surgical Pathology, 2016
- PI-RADS Prostate Imaging – Reporting and Data System: 2015, Version 2European Urology, 2016
- Efficient interval estimation for age-adjusted cancer ratesStatistical Methods in Medical Research, 2006